Nike Appoints Pfizer CFO David Denton as New Finance Chief
Nike named Pfizer CFO David Denton as its next CFO, replacing Matthew Friend effective August 17. Denton, with experience at Pfizer, Lowe’s, and CVS Health, receives a compensation package including a $1.45 million salary and $7.25 million sign-on award. The change comes as Nike faces declining sales in Greater China (projected 20% drop) and a broader turnaround under CEO Elliott Hill. The company also flagged tariff refunds boosting Q4 fiscal 2026 earnings.
Cross-source coverage
Wire timeline
Nike appoints David Denton as new CFO
Nike has appointed David Denton as its new Executive Vice President and Chief Financial Officer, effective August 17, 2026. Denton will replace Matthew Friend, who will stay until September 4 to assist with the transition. Denton, previously CFO and EVP at Pfizer since 2022, will lead Nike's global finance organization and work with CEO Elliott Hill on financial execution, capital allocation, and long-term value creation. His past roles include CFO at Lowe's Companies and board positions at Haleon and Tapestry. Separately, Nike announced its Q4 fiscal 2026 results, due June 30, will include a benefit from tariff refunds not previously guided, while excluding that one-off benefit, results are expected to be broadly in line with prior guidance.
Yahoo FinanceNike names former Pfizer CFO David Denton as finance chief
Nike announced that David Denton, former CFO of Pfizer, will join the company as executive vice president and chief financial officer, effective August 17. Denton will oversee Nike's global finance organization and work with CEO Elliott Hill on capital allocation and growth. He replaces Matthew Friend, who will stay until September 4 to assist the transition. Denton previously served as CFO at Pfizer since 2022 and at Lowe's from 2018 to 2022. Jefferies analysts view the appointment as a deliberate step in Hill's turnaround strategy, noting the timing ahead of Nike's fiscal 2027 planning cycle. Denton brings experience from managing large global businesses and governance roles on boards including Haleon and Tapestry. Nike shares traded down 2% on the day of the announcement.
Yahoo FinanceNike names former Pfizer CFO David Denton as finance chief
Nike Inc has appointed David Denton, former CFO of Pfizer, as its new executive vice president and chief financial officer, effective August 17. Denton will lead Nike's global finance organization and work with CEO Elliott Hill on capital allocation, financial discipline and long-term growth. He succeeds Matthew Friend, who will support the transition until September 4. Denton brings experience from Pfizer (2022-2026), Lowe's (2018-2022) and CVS Health. Jefferies analysts view the appointment as a deliberate step in Nike's turnaround strategy under its Sport Offense operating model, noting the timing ahead of fiscal 2027 planning and Q4 results, which will include a tariff refund benefit. Nike shares traded down 2% on the announcement day.
Yahoo FinanceNike's Surprise CFO Change Signals Turnaround Progress
Nike announced a planned CFO transition, with longtime CFO Matthew Friend leaving and being replaced by Pfizer CFO David Denton, effective August 17. Friend, a nearly 20-year Nike veteran, will stay as an adviser through September 4 and participate in the Q4 earnings call. Denton, with over 30 years of experience including CFO roles at Lowe's and CVS, will receive a $1.45 million base salary plus incentives. Analysts expressed surprise at the timing, just before Q4 earnings, suggesting Nike may cut annual guidance again. BNP Paribas noted this would be Friend's fifth initial annual guide cut. However, Jefferies viewed the change as 'another tangible signal' that CEO Elliott Hill's turnaround is progressing methodically. Some analysts raised concerns about Denton's lack of activewear industry experience, though precedent exists with former CFO Don Blair joining from PepsiCo. Nike also announced an unspecified tariff refund providing a one-time Q4 benefit.
Yahoo FinanceNike Names Pfizer CFO David Denton as New Chief Financial Officer
Nike announced on Monday that it has appointed David Denton, currently CFO of Pfizer Inc., as its next chief financial officer, replacing Matthew Friend. The transition is effective August 17, with Friend staying in an advisory role until September 4. Denton, 60, brings over three decades of finance experience at major public companies, including stints as CFO at Lowe's and CVS Health. His compensation package includes a $1.45 million base salary, a 120% bonus target, $11.5 million in annual long-term incentives, and a $7.25 million sign-on award to replace forfeited equity from Pfizer. The move comes as Nike navigates a sluggish turnaround under CEO Elliott Hill, who took over in October 2024. The company is facing persistent sales declines, particularly in Greater China where a 20% drop is projected, and ongoing challenges with the Converse brand. Nike also flagged an unplanned boost to its upcoming Q4 fiscal 2026 earnings from tariff refunds, though underlying performance remains in line with prior forecasts.
Yahoo FinanceNike names Pfizer CFO David Denton to replace Matthew Friend
Nike announced on Monday that it has appointed Pfizer CFO David Denton as its next Chief Financial Officer, replacing Matthew Friend as the sportswear giant grapples with a prolonged sales slump and turnaround efforts. The transition will take effect on August 17, with Friend remaining in an advisory role until September 4. Denton, 60, brings over three decades of finance experience from major public companies including Pfizer, Lowe's, and CVS Health. His compensation package includes a $1.45 million base salary, a 120% bonus target, $11.5 million in long-term incentive awards, and a $7.25 million sign-on cash payment to offset forfeited equity from Pfizer. The leadership change comes as Nike's new CEO Elliott Hill, who took over in October 2024, pushes the company back toward its athletic roots and rebuilds wholesale relationships, while facing persistent headwinds in Greater China and with the Converse brand. Nike's current-quarter outlook projects revenue contraction of 2-4%, with China alone expected to decline 20%. The company also flagged unplanned tariff refunds that will boost its upcoming fiscal Q4 report on June 30.
Yahoo FinanceNike Discloses CFO Transition
Nike Inc. announced that executive vice president and CFO Matthew Friend will step down, effective August 17, 2026. He will be succeeded by David M. Denton, currently CFO at Pfizer. Friend will remain with the company through September 4 to support an orderly transition and will participate in Nike's fourth-quarter fiscal 2026 earnings call on June 30. Denton, who brings over 30 years of finance and operating leadership experience from Pfizer, Lowe's, CVS Health, and Deloitte, will partner with CEO Elliott Hill and senior leadership to support disciplined execution, capital allocation, and long-term value creation. The move is part of broader leadership changes at Nike as it shifts from foundational actions to sustained growth through its 'Sport Offense operating model.' Recent leadership changes include César Garcia as VP and GM of EMEA and Cathy Sparks as VP and GM of Greater China.
Yahoo FinanceNike Names Pfizer’s Denton as Next CFO
Nike has appointed David Denton, an executive from Pfizer, as its next Chief Financial Officer, effective August 17. Denton will succeed Matthew Friend, who will remain through September 4 to assist with the transition. The announcement comes as Nike is struggling to execute a turnaround under CEO Elliott Hill, with declining sales in the key China market. The move signals a strategic reshuffling at the beleaguered sneaker and apparel company as it seeks to stabilize its financial leadership amid ongoing operational challenges.
Yahoo Finance